Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is a leader in the insulin delivery and diabetes management industry, backed by a strong pipeline of innovative products and a global presence. Despite facing competition and regulatory risks, the company is expected to achieve steady revenue growth and improved profitability margins, as evidenced by their high Time in Range (TIR) and praise from physicians for their AID systems. The company's strong balance sheet and progress in exiting agreements with Medtronic further reinforce a positive outlook for MiniMed.

Bears say

Minimed Group is currently facing several challenges in the market, including intense competition, potential pricing pressure, and shifting market dynamics. Additionally, the company's profitability profile and cash generation capabilities, while compelling, may be hindered by factors such as inflationary input costs and CGM pricing pressures. The success of MiniMed's new product launches will be crucial in regaining a competitive advantage in the fast-moving diabetes tech segment, and the company's close relationship with Medtronic, which still holds a majority ownership, poses potential risks.

MMED has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 11 analysts, MMED has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.